8-K: Carlsmed Q2 Revenue Soars 99% on AI Spine Tech Adoption

Carlsmed, Inc. reported a 99% year-over-year revenue increase to $12.1 million in Q2 2025, driven by its AI-enabled aprevo platform, and reaffirmed full-year guidance.

Summary

• Revenue for the second quarter of 2025 reached $12.1 million, marking a 99% increase compared to $6.1 million in the second quarter of 2024.
• Gross profit for Q2 2025 was $8.9 million, up from $4.6 million in Q2 2024.
• Gross margin decreased to 73.4% in Q2 2025 from 75.0% in Q2 2024, primarily due to expedite production fees charged by contract manufacturers.
• Operating expenses increased to $15.4 million in Q2 2025 from $10.9 million in Q2 2024, driven by higher personnel costs, sales and marketing expansion, and public company transition expenses.
• Net loss for Q2 2025 was $6.8 million, a slight increase from $6.3 million in Q2 2024.
• Adjusted EBITDA loss remained flat at $6.2 million for both Q2 2025 and Q2 2024.
• Cash and cash equivalents stood at $33.5 million as of June 30, 2025.
• The company received $93.5 million in net proceeds from its initial public offering in July 2025.
• Carlsmed successfully completed the first personalized cervical spine surgery using its aprevo technology platform in July 2025.
• aprevo cervical procedures received CMS New Technology Add-On Payment (NTAP) reimbursement, effective October 1, 2025.
• Full-year 2025 revenue guidance is maintained in the range of $45.5 million to $47.5 million, representing 67% to 75% growth over 2024.

Sentiment

Score: 7

Explanation: The strong revenue growth and strategic advancements like the cervical spine surgery and NTAP reimbursement are significant positives. However, the increased net loss and decreased gross margin due to production costs temper the overall sentiment, indicating a growth-stage company with ongoing investment needs.

Positives

• Strong revenue growth of 99% year-over-year, reaching $12.1 million in Q2 2025, driven by increased surgical procedures utilizing the aprevo technology platform.
• Successful completion of the first personalized cervical spine surgery using aprevo technology in July 2025, expanding the product offering.
• Receipt of CMS New Technology Add-On Payment (NTAP) reimbursement for aprevo cervical procedures, effective October 1, 2025, which is expected to enhance market adoption and revenue.
• Significant capital infusion of $93.5 million net proceeds from the initial public offering in July 2025, substantially strengthening the balance sheet.
• Reaffirmed full-year 2025 revenue guidance of $45.5 million to $47.5 million, indicating continued strong growth expectations (67% to 75% over 2024).

Negatives

• Net loss increased to $6.8 million in Q2 2025 from $6.3 million in Q2 2024, reflecting ongoing investment in growth.
• Gross margin decreased to 73.4% in Q2 2025 from 75.0% in Q2 2024, primarily due to expedite production fees charged by contract manufacturers.
• Operating expenses significantly increased by $4.5 million year-over-year, driven by higher personnel costs, sales and marketing expansion, and costs associated with the transition to being a publicly traded company.
• Cash and cash equivalents decreased to $33.472 million as of June 30, 2025, from $40.125 million as of December 31, 2024, prior to the IPO proceeds.

Risks

• The company faces risks detailed in the 'Risk Factors' section of its Registration Statement on Form S-1, which could cause actual results to differ materially from forward-looking statements.
• Gross margin was negatively impacted by expedite production fees charged by contract manufacturers, indicating potential supply chain or production cost challenges.
• Continued operating losses are expected as the company invests heavily in research and development, sales and marketing, and general and administrative functions to support growth.
• The ability to successfully scale the aprevo technology platform and achieve the projected full-year revenue guidance is subject to various important factors.

Future Outlook

Carlsmed expects full-year 2025 revenue to be in the range of $45.5 million to $47.5 million, representing 67% to 75% growth over 2024. The company anticipates commercially launching its aprevo cervical technology platform in the United States in 2026 and aims to become the new standard of care in spine fusion surgery.

Management Comments

• "Our strong commercial performance was driven by the continued adoption of our highly differentiated AI-enabled aprevo technology platform and growing recognition of its ability to deliver more favorable patient outcomes than legacy devices."
• "Building upon our momentum in personalized lumbar fusion surgery, in July we successfully completed the first personalized cervical spine surgery using our aprevo technology platform, launching in 2026."
• "We enter the second half of 2025 well positioned for continued scale as we become the new standard of care in spine fusion surgery."

Industry Context

Carlsmed operates in the rapidly evolving medical technology sector, specifically targeting spine surgery with AI-enabled personalized solutions. The successful completion of the first personalized cervical spine surgery and the securing of CMS NTAP reimbursement for aprevo cervical procedures position the company to capitalize on the growing demand for advanced, outcome-driven surgical technologies. The focus on AI and personalized approaches aligns with broader industry trends towards precision medicine and digital health integration in surgical fields, aiming to improve patient outcomes and reduce healthcare costs.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, successful IPO, and strategic expansion into cervical spine surgery with reimbursement. Potential concern from increased net loss and gross margin pressure.
• Patients: Positive impact from the continued adoption of AI-enabled aprevo technology, which aims to deliver more favorable patient outcomes, and the expansion into cervical spine surgery.
• Employees: Increased personnel costs in R&D, sales, marketing, and G&A suggest continued hiring and growth opportunities.
• Customers (Hospitals/Surgeons): Continued access to innovative AI-enabled personalized spine surgery solutions, with expanded offerings (cervical spine) and improved reimbursement pathways.
• Suppliers (Contract Manufacturers): Increased demand for production, but also pressure on costs as indicated by expedite production fees.

Next Steps

• Continue scaling the impact of the aprevo technology platform.
• Advance the personalized spine surgery platform to transform patient outcomes and drive long-term growth.
• Commercially launch aprevo cervical in the United States in 2026.
• Host a conference call and webcast on August 28, 2025, at 4:30 pm Eastern Time to discuss Q2 and first-half 2025 performance.

Key Dates

Recommendation

While Carlsmed demonstrates impressive revenue growth and strategic advancements with its AI-enabled aprevo platform, including the successful first cervical spine surgery and securing NTAP reimbursement, the company is still in a high-growth, high-investment phase. The increased net loss and slight gross margin compression due to production costs indicate that profitability remains a future goal. The recent IPO provides significant capital, but the stock's valuation likely already reflects much of the positive news. A 'hold' recommendation is appropriate for investors to observe the execution of the cervical launch in 2026 and the path to improved profitability and sustained gross margins, especially given the reaffirmed but broad full-year guidance.

Keywords

Carlsmed, aprevo, AI-enabled spine surgery, medical technology, personalized medicine, lumbar fusion, cervical spine surgery, Q2 2025 earnings, financial results, NTAP reimbursement, IPO, Nasdaq: CARL